We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
The contribution of the individual blood elements to the variability of thromboelastographic measures.
Transfusion 2018 October
BACKGROUND: Thromboelastography (TEG) is widely advocated as a rapid method for obtaining critical blood coagulation data to guide resuscitation, but the method suffers well-known limits in sensitivity, repeatability, and interpretability.
STUDY DESIGN AND METHODS: Mixtures of fresh human blood components were prepared that represent the range of blood element concentrations seen in health and disease and after injury. These mixtures were tested in a TEG device after kaolin, tissue factor and phospholipid, or tissue factor and phospholipid with abciximab activation. The results were measured as reproducibility and nonlinear effects in regression analysis and evaluated for interpretability.
RESULTS: Clot strength was associated with increased platelet (PLT) content and plasma fibrinogen concentration and content. Increasing hematocrit (Hct) reduced while increasing PLT or plasma concentration increased TEG clot strength. The abciximab dose used to block PLT activity did not fully inhibit the PLT contribution to clot strength. Clot strength is logarithmically correlated in the absence and linearly correlated to PLT concentration in the presence of abciximab. TEG clot strength with or without abciximab is dependent on Hct, PLT, and plasma (fibrinogen) concentrations in complex patterns.
CONCLUSION: Interpretation of TEG variables is limited without knowledge of the concentration of the blood components present. When "normal" TEG values are known for a certain PLT-plasma-red blood cell concentration, the assay can be used to assess PLT and plasma function in coagulation. The TEG "functional fibrinogen" assay should be used only as a gross estimate of the fibrinogen concentration in whole blood.
STUDY DESIGN AND METHODS: Mixtures of fresh human blood components were prepared that represent the range of blood element concentrations seen in health and disease and after injury. These mixtures were tested in a TEG device after kaolin, tissue factor and phospholipid, or tissue factor and phospholipid with abciximab activation. The results were measured as reproducibility and nonlinear effects in regression analysis and evaluated for interpretability.
RESULTS: Clot strength was associated with increased platelet (PLT) content and plasma fibrinogen concentration and content. Increasing hematocrit (Hct) reduced while increasing PLT or plasma concentration increased TEG clot strength. The abciximab dose used to block PLT activity did not fully inhibit the PLT contribution to clot strength. Clot strength is logarithmically correlated in the absence and linearly correlated to PLT concentration in the presence of abciximab. TEG clot strength with or without abciximab is dependent on Hct, PLT, and plasma (fibrinogen) concentrations in complex patterns.
CONCLUSION: Interpretation of TEG variables is limited without knowledge of the concentration of the blood components present. When "normal" TEG values are known for a certain PLT-plasma-red blood cell concentration, the assay can be used to assess PLT and plasma function in coagulation. The TEG "functional fibrinogen" assay should be used only as a gross estimate of the fibrinogen concentration in whole blood.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app